Clinical Trials Browser

Phase 1 × Uveal Melanoma × Cyclophosphamide × Clear all

Uveal Melanoma, Melanoma

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT01046487 2026-03-13

PALANGI3

Phase 1 Completed

26 enrolled

DermatologicGastrointestinalSarcoma

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT05075993 2025-12-26

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Phase 1 Active not recruiting

352 enrolled

DermatologicGastrointestinalGynecologicSarcoma

Uveal Melanoma, Carcinoma, Hepatocellular, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms

NCT03068624 2024-01-25

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Phase 1 Unknown

34 enrolled

Dermatologic

Uveal Melanoma

Clinical Trials

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

PALANGI3

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma